Skip to content
HowShorted

OCULAR THERAPEUTIX, INC short interest in 2025

In 2025, OCULAR THERAPEUTIX, INC's disclosed short interest ran from 7.10% of shares outstanding on 15 Jan 2025 to 5.79% on 31 Dec 2025, a change of -1.31 percentage points. The year's high was 9.29% on 15 Jul 2025 and its low 4.97% on 15 Dec 2025, averaging 7.67% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.70 days on 28 Feb 2025. Full history: OCULAR THERAPEUTIX, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for OCULAR THERAPEUTIX, INC in 2025

2025 in figures

Start of year
7.10% (15 Jan 2025)
End of year
5.79% (31 Dec 2025)
Change
-1.31 pp
High
9.29% (15 Jul 2025)
Low
4.97% (15 Dec 2025)
Average
7.67%
Highest days to cover
13.70 (28 Feb 2025)
SEC filings marked
8

Every report in 2025

OCULAR THERAPEUTIX, INC short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20257.10%12.34
31 Jan 20256.92%12.40
14 Feb 20257.38%11.38
28 Feb 20257.66%13.70
14 Mar 20258.16%6.1910-K filed, results (8-K)
31 Mar 20258.01%7.71
15 Apr 20258.97%7.03
30 Apr 20258.26%9.86
15 May 20258.68%7.6710-Q filed, results (8-K)
30 May 20258.95%8.21
13 Jun 20259.05%4.42
30 Jun 20258.90%5.58
15 Jul 20259.29%6.21
31 Jul 20258.06%7.11
15 Aug 20257.52%5.6210-Q filed, results (8-K)
29 Aug 20257.95%8.13
15 Sep 20258.78%5.58
30 Sep 20257.79%5.00
15 Oct 20257.81%3.05
31 Oct 20256.47%6.46
14 Nov 20256.18%6.8910-Q filed, results (8-K)
28 Nov 20255.46%3.80
15 Dec 20254.97%2.33
31 Dec 20255.79%4.32

See also: OCULAR THERAPEUTIX, INC's full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.